Skip to main content
. 2018 Nov 30;5(2):80–90. doi: 10.1093/ehjcvp/pvy044

Figure 3.

Figure 3

Hazard ratios for first outcome event (on-treatment analysis): PSM dabigatran vs. rivaroxaban cohort. Note: numbers of events across subtypes of an outcome may exceed the total number of events for that outcome as a patient can be diagnosed with >1 condition. Cox regression analyses. Hazard ratios were not calculated for major urogenital bleeding. CI, confidence interval; PSM, propensity score matched.